(2E)-1-(2,4-dimethoxyphenyl)-3-(3-fluorophenyl)prop-2-en-1-one, 95.0%, 2g

(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-((1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl)amino)butanoic acid, 98%, 5g

1-((4-(2-Methoxyphenoxy)phenyl)sulfonamido)cyclohexane-1-carboxylic acid, 97%, 1g

Tert-butyl n-(4-amino-2-methoxyphenyl)carbamate, 97%, 2.5g

Trimethyl((4-nitrophenyl)ethynyl)silane, 95+%, 10g

1,12-Dodecanedicarboxylic acid, 95.0%, 100g

E-Plan phase EPLPHi 20x/0.40 infinity corrected IOS objective. Working distance 2.61 mm

2-AMINO-N-CYCLOBUTYLACETAMIDE, 95.0%, 100mg

4-Isopropyl-2-methylpyrimidine-5-carboxylic acid, 95%, 250mg

(1-ETHENYL-2-OXABICYCLO[2.2.2]OCTAN-4-YL)METHANOL, 95.0%, 10g

3-Bromo-2,6-dichlorobenzaldehyde, 98%, 250mg

Adhesion slides Histobond® Edges ground 90°, orange 100 pcs

tert-Butyl (2R,3R)-3-hydroxy-2-methylazetidine-1-carboxylate, 98%, 500mg